To uncover the mechanistic underpinnings of tbLN specific blockade of CTLA4/CD80/86 axis resulting in a superior anti-tumor response, the immunome of mice treated with anti-CTLA4 through different drug delivery strategies was interrogated. This evidence concerns the gene CD80 and neoplasm.